News | May 31, 2021
Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The facility is expected to be completed in 2024
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
The price increases are due to the rising costs of raw materials.
Subscribe To Our Newsletter & Stay Updated
